Imara Completes Patient Enrollment for Ardent Trial Testing IMR-687

Imara Completes Patient Enrollment for Ardent Trial Testing IMR-687

303169

Imara Completes Patient Enrollment for Ardent Trial Testing IMR-687

Imara has completed patient enrollment for its Phase 2b Ardent clinical trial, which is testing the safety and efficacy of IMR-687 for the treatment of sickle cell disease (SCD). “We are excited to have enrolled [participants] from across the world, including in Africa, making this a truly global effort,” Rahul Ballal, PhD, president and CEO of Imara, said in a press release. The Ardent trial (NCT04474314) had sought to recruit an estimated 99 patients with SCD…

You must be logged in to read/download the full post.